Obtained enormous global visibility and tremendous response from the authors and readers from all over the world inspired the publisher to maintain reputed Open Access Journals in various scientific disciplines. The journals have over 15 million readers and the reputation and success earned can be attributed to the strong Editorial Board which contains over 50, eminent personalities that ensure a rapid, qualitative and quick review process. More than International Societies are supporting in making scientific information Open Access.
Additionally, the Company announced potential upcoming milestones and recent corporate developments. We are successfully executing our strategic plan to advance our innovative cancer treatment solutions through the regulatory process and work our way toward accelerated FDA approvals by focusing on significant unmet needs.
Our recent accomplishments include: Annamycin clinical site with a fourth, we believe, to come in the near term; commencing treatment for the first patient enrolled in the Annamycin U. Clinical trial Refractory hematological malignancies innovative drug market The University Hospitals Cleveland Medical Center, which includes the Seidman Cancer Center and the Cleveland Clinic; announcing the opening of enrollment for a physician-sponsored clinical trial of WP for the treatment of glioblastoma and brain metastases in adults; initiating operations in Australia to benefit from potential rebates of up to In our mission to develop breakthrough treatments for rare and difficult cancers, we have developed unique attributes in certain compounds that we believe will: We believe our three highly differentiated technologies have the potential to effectively attack high profile acute cancer states, ranging from AML; brain tumors; deadly forms of skin cancer; to pancreatic cancer.
We currently have two oncology drugs in clinical trials, Annamycin and WP, a physician-sponsored trial, with the possibility of two others commencing clinical trials in This is only possible because of the tireless dedication and the hard work of all our associates at Moleculin.
We are highly focused on leveraging our successes to potentially change the treatment for cancer and excited about the opportunities ahead.
We believe that the latter will generate Australian income tax credits next calendar year for which cash should be received by our Australian subsidiary in Foster, executive vice president and chief financial officer of Moleculin. Published research supports the belief that Cutaneous T-Cell Lymphoma, a deadly form of skin cancer, may be highly dependent on the upregulation of the activated form of STAT3.
Moleculin Announces Enrollment Opens for Brain Tumor Trial of WP - July 31,the Company announced enrollment opened for a physician-sponsored clinical trial of WP for the treatment of glioblastoma and brain metastases in adults.
This is the first investigator-initiated trial of WP, an important milestone.
The goal of this clinical research study is to find the highest tolerable dose of WP that can be given to patients with recurrent has returned after treatment cancerous brain tumors or melanoma that has spread to the brain. The safety of this drug will also be studied. WP is designed to target the STAT3 pathway in cancer cells, which independent research has shown allows these cells to survive and proliferate, increases new blood vessels to the tumor, causes the cancer cells to move throughout the body and brain, and reduces the ability of the immune system to effectively combat tumor development.
In addition, the Company believes that WP may also have the potential to stimulate a natural anti-tumor immune response. The Australian subsidiary provides a great opportunity to speed up preclinical development and reduce the overall cost of continued drug development efforts. Consent from the Polish National Office was the final step required to allow recruitment of patients for this important trial.
The Company believes the water-soluble nature of WP could make it an ideal candidate for targeting these unique and highly metastatic tumors. The Company believes WP represents a major expansion of its STAT3 inhibition capability by providing a highly soluble alternative that is ideally suited for IV administration.
This agreement marks the beginning of creating a preclinical package to submit to the FDA in order to request Investigational New Drug status. Bringing validated innovations from USA to Poland. A to expand production capacity for Annamycin.
BSP has a solid track record for supplying liposomal formulations to large pharmaceutical companies.
General and Administrative Expense. Such increases are due to the increased corporate activity as the Company enters clinical trials and increases its pre-clinical work on WP Concurrently with the sale of the common shares, the Company also sold warrants to the investorsshares of common stock.
The warrants are exercisable for five years from the initial exercise date. The closing of the sales of these securities under the agreement occurred on June 22, Innovative approach to treating unmet need has been handsomely rewarded in the past through in-licensing or outright acquisition of the mature/nascent product/innovator company at a premium.
The report provides an overview of the approved therapies for RRMM, NDMM, AML, MDS, unmet need and limitations of the current SOC for .
What we do: Mundipharma EDO GmbH (EDO) is a company focused on the preclinical and clinical development of treatments for cancer types where there are currently limited options for patients. Argenx discovers, designs and develops innovative antibody therapeutics for its own pipeline of treatments for cancer and autoimmune diseases and for its partners.
Harnessing our technology and know-how, we aim to meet the needs of patients by engineering antibodies to target diseases too complex for other antibody technologies. Open Access Initiative is committed to make genuine and reliable contributions to the scientific community without restricting the access of published content.
According to the American Society of Hematology, hematological malignancies or blood cancers affect production and function of blood cells. Most of these cancers start in the bone marrow where blood is produced. Stem cells in bone marrow mature and develop into three types of blood cells: red blood cells, white blood cells, or platelets.
3 Biggest Breakthroughs In Cancer Treatment In 30 December On April 27, , the FDA approved the first liver cancer drug in over a decade by expanding the use of Bayer AG’s (NASDAQOTH: BAYRY) Stivarga (regorafinib) to include treatment of patients with Hepatocellular Carcinoma who have been previously treated with the drug sorafenib.